-
Following the relaxation of lockdown measures in China on November 11, 2022, there was a rapid uptick in coronavirus disease 2019 (COVID-19) cases from November to December 2022. By January 31, 2023, Beijing observed a cumulative infection rate of 92.3% (1). The urgent necessity now pertains to the evaluation of the short-term and long-term impacts of COVID-19 on the Chinese population. Long COVID-19, classified by the World Health Organization (WHO) as the persistence of symptoms for 12 weeks post-infection, is alarming in various countries (2). However, it remains inadequately explored in China’s context, especially pertaining to the 2022 outbreak (3). Beyond the physical implications, the psychological ramifications of COVID-19 are increasingly concerning. Factors such as the stress associated with medical care, extensive hospital stays, social isolation, and stigma substantially contribute to prolonged mental health issues, including depression, anxiety, insomnia, and posttraumatic stress disorder (PTSD) (4). Furthermore, research accentuates the varying duration and severity of COVID-19 symptoms across different populations. Healthcare workers (HCWs) appear to be particularly susceptible (5). Thus, this research aims to conduct a comprehensive examination of the long-term physical and psychological symptoms among the community and HCWs, aiming to enhance epidemic prevention policies and health care support in the post-COVID-19 era.
In this research, two cohorts were established in January 2023: a HCW cohort comprised of 6,237 participants from Peking University Third Hospital (PUTH), a tertiary institution in Beijing Municipality, and a community-based cohort with 2,011 participants. The latter was enlisted from four Beijing communities, including 528 civilians from PUTH’s Second Outpatient Department in the Haidian District, 574 from the Dongpingli Community in the Chaoyang District, 360 from the Zizhuyuan Community in the Haidian District, and 549 teachers and students associated with Peking University Health Science Center. A digital survey was employed to collect participants’ demographics and COVID-19 infection details such as infection date, onset symptoms within two weeks, duration of symptoms, treatment received, and vaccination status (6–8). Infection was diagnosed based on a positive result from either an antigen test or a nucleic acid test. Two follow-up periods were conducted: the first from March 1 to 10, 2023 (approximately three months post-outbreak), and the second from April 20 to 30, 2023 (roughly five months post-outbreak). During each follow-up, participants filled out an online questionnaire, detailing symptoms they experienced within the preceding week and the duration of symptoms. Furthermore, the Depression Anxiety and Stress Scale (DASS-21) was utilized to evaluate participants’ mental health condition. By the end of the study, 4,229 HCWs and 1,287 community members had successfully completed the entire process, of which 3,309 HCWs and 1,069 community individuals, who had contracted the virus, were included in the final analysis.
The statistical analysis was executed with the use of R software (version 4.1.0, R core team, Vienna, Austria). We represent qualitative data as frequencies (percentages), which have been compared via the chi-square test or Fisher’s exact test. The measurement of recovery time was conducted in days and juxtaposed between groups utilizing Kaplan-Meier analysis. To control for potential confounders, such as age, sex, history of illness, and vaccination status, Cox regression analysis was carried out. The DASS-21 was deployed to compute scores for stress, depression, and anxiety, which were then compared between groups using the Mann-Whitney nonparametric test. Log-binomial regression was additionally used to control confounders. A P-value of less than 0.05 was deemed statistically significant.
Among 4,229 HCWs, 3,309 (78.2%) were infected with COVID-19. Within the broader community sample of 1,287 individuals, 1,069 (83.1%) were infected (Table 1). The average ages for the infected persons were 37.4±9.8 years for HCWs, and 41.7±17.4 years for the community cohort, respectively. Preexisting medical conditions were reported in 25.5% of the HCWs and 37.0% of the community cohort. Regarding COVID-19 vaccination, 95.8% of HCWs and 92.6% of the community cohort had received the vaccine. Furthermore, 38.7% of HCWs had been administered the adenovirus-based vaccine.
Characteristics of participants Community (N=1,069) HCW (N=3,309) P Age (mean±SD) 41.67±17.43 37.40±9.80 0.003 Gender, n (%) Male 388 (36.3) 903 (27.3) <0.001 Female 681 (63.7) 2,406 (72.7) History of disease, n (%) Hypertension 175 (16.4) 273 (8.3) <0.001 Diabetes 88 (8.2) 109 (3.3) <0.001 Hyperlipidemia 142 (13.3) 305 (9.2) <0.001 Respiratory disease 47 (4.4) 76 (2.3) <0.001 Cardiovascular disease 55 (5.1) 16 (0.5) <0.001 Kidney disease 12 (1.1) 26 (0.8) 0.302 Digestive system diseases 56 (5.2) 90 (2.7) <0.001 Immune system diseases 10 (0.9) 38 (1.1) 0.561 Reproductive system diseases 44 (4.1) 121 (3.7) 0.493 Any 396 (37.0) 845 (25.5) <0.001 Vaccination, n (%) Inactivated vaccine 952 (89.1) 2,922 (88.3) 0.504 Adenovirus injection vaccine 32 (3.0) 1,281 (38.7) <0.001 Adenovirus inhalation vaccine 18 (1.7) 165 (5.0) <0.001 mRNA vaccine 3 (0.3) 192 (5.8) <0.001 Recombinant protein vaccine 10 (0.9) 187 (5.7) <0.001 Any 990 (92.6) 3,171 (95.8) <0.001 Abbreviation: SD=standard deviation; HCW=healthcare worker. Table 1. Basic demographic characteristics of the community population and HCWs — Beijing Municipality, China, December 2022–April 2023.
As depicted in Table 2, a significant majority of both the community population (95.3%) and HCWs (97.0%) reported experiencing at least one acute symptom. Interestingly, HCWs exhibited higher rates of acute symptoms as compared to the community population overall. A notable decrease in symptom occurrence was observed between the first and second follow-ups: by the 3-month mark, 54.3% of the community population and 59.0% of HCWs reported an absence of symptoms. This increased to 60.8% and 71.3% respectively, five months post COVID-19 infection. At the final follow-up session, the most frequently reported symptoms among both groups were fatigue or weakness (19.2% community vs. 18.2% HCWs), sleep disruptions (10.0% vs. 7.7%), cognitive dysfunction (9.0% vs. 9.5%), hair loss (5.7% vs. 6.1%), musculoskeletal discomfort (5.1% vs. 4.4%), and persistent cough (5.1% vs. 5.0%). Interestingly, five months post COVID-19 onset, HCWs had a lower symptom prevalence compared to the community population, with the exceptions of cognitive dysfunction and diminished interest.
Symptoms Acute symptoms First follow-up Second follow-up Community HCW P Community HCW P Community HCW P (N=1,069) (N=3,309) N=1,069 (N=3,309) (N=1,069) (N=3,309) Anyone of the following symptoms No 50 (4.7) 99 (3.0) 0.011 580 (54.3) 1,953 (59.0) <0.001 650 (60.8) 2,359 (71.3) <0.001 Yes 1,019 (95.3) 3,210 (97.0) 489 (45.7) 1,134 (34.3) 419 (39.2) 950 (28.7) Fatigue/tired or weakness 716 (67.0) 2,555 (77.2) <0.001 308 (28.8) 744 (22.5) <0.001 205 (19.2) 603 (18.2) 0.513 Smell disorder 306 (28.6) 1,267 (38.3) <0.001 51 (4.8) 94 (2.8) <0.001 29 (2.7) 73 (2.2) 0.402 Hypogeusia 345 (32.3) 1,372 (41.5) <0.001 51 (4.8) 73 (2.2) <0.001 31 (2.9) 62 (1.9) 0.057 Shortness of breath or breathlessness 162 (15.2) 734 (22.2) <0.001 37 (3.5) 106 (3.2) <0.001 41 (3.8) 77 (2.3) 0.011 Cough 645 (60.3) 2,679 (81.0) <0.001 107 (10.0) 218 (6.6) <0.001 55 (5.1) 165 (5.0) 0.900 Headache 384 (35.9) 1,529 (46.2) <0.001 49 (4.6) 129 (3.9) <0.001 37 (3.5) 109 (3.3) 0.868 Problems sleeping 280 (26.2) 1,099 (33.2) <0.001 123 (11.5) 351 (10.6) <0.001 107 (10.0) 256 (7.7) 0.023 Joint or muscle pain 498 (46.6) 1,886 (57.0) <0.001 78 (7.3) 170 (5.1) <0.001 54 (5.1) 147 (4.4) 0.457 Cognitive dysfunction 261 (24.4) 1,095 (33.1) <0.001 109 (10.2) 409 (12.4) <0.001 96 (9.0) 313 (9.5) 0.684 Chest pain 153 (14.3) 671 (20.3) <0.001 36 (3.4) 99 (3.0) <0.001 40 (3.7) 81 (2.4) 0.033 Change in mood 80 (7.5) 373 (11.3) 0.001 29 (2.7) 107 (3.2) <0.001 33 (3.1) 103 (3.1) >0.999 Decreased interest 98 (9.2) 424 (12.8) 0.002 27 (2.5) 96 (2.9) <0.001 26 (2.4) 84 (2.5) 0.936 Stomach pain 110 (10.3) 473 (14.3) 0.001 31 (2.9) 77 (2.3) <0.001 40 (3.7) 63 (1.9) 0.001 Hair loss 103 (9.6) 415 (12.5) 0.012 45 (4.2) 215 (6.5) <0.001 61 (5.7) 201 (6.1) 0.714 Diarrhea 111 (10.4) 612 (18.5) <0.001 16 (1.5) 38 (1.1) <0.001 13 (1.2) 37 (1.1) 0.923 Sore throat 394 (36.9) 1,888 (57.1) <0.001 53 (5.0) 132 (4.0) <0.001 41 (3.8) 116 (3.5) 0.682 Fever 596 (55.8) 2,252 (68.1) <0.001 26 (2.4) 66 (2.0) <0.001 10 (0.9) 50 (1.5) 0.209 Chilliness 225 (21.0) 1,105 (33.4) <0.001 30 (2.8) 61 (1.8) <0.001 30 (2.8) 51 (1.5) 0.011 Palpitations 172 (16.1) 829 (25.1) <0.001 53 (5.0) 212 (6.4) <0.001 41 (3.8) 139 (4.2) 0.664 Nausea/vomiting 104 (9.7) 506 (15.3) <0.001 13 (1.2) 26 (0.8) <0.001 9 (0.8) 26 (0.8) >0.999 Postexertional malaise 117 (10.9) 775 (23.4) <0.001 52 (4.9) 180 (5.4) <0.001 45 (4.2) 130 (3.9) 0.751 Abbreviation: HCW=healthcare worker. Table 2. Acute and chronic symptoms reported at each follow-up among the community population and HCWs — Beijing Municipality, China, December 2022–April 2023, n (%).
Figure 1 demonstrates that among HCWs, the median recovery period amounted to 41 days. This duration is notably shorter than the median recovery span of 62 days observed within the broader community. The latter group reported prolonged recovery times relating to symptoms such as breathlessness, cognitive dysfunction, chest discomfort, reduced interest, hair loss, and palpitations, with the median recovery terms being equal to or surpassing 60 days. Conversely, HCWs exhibited prolonged symptoms such as reduced interest, hair loss, mood changes, palpitations, breathlessness, and chest discomfort. It’s worth noting that, except for mood changes that took longer to resolve, HCWs generally reported faster symptom resolution in comparison to the community cohort.
Figure 1.Duration of recovery for the community population and HCWs — Beijing Municipality, China, December 2022–April 2023. (A) The overall recovery duration among HCWs and the general population. (B) The median recovery duration for each symptom was also determined.
Note: The adjusted P-value was calculated using Cox regression, taking into account confounding variables such as age, gender distribution, history of any disease, and vaccination status. Recovery time, measured in days, was compared between these groups using Kaplan-Meier analysis in panel A.
Abbreviation: HCWs=healthcare workers; IQR=interquartile range.
Psychological symptom scores, including those indicating stress, depression, and anxiety, demonstrated a decreasing trend following infection with COVID-19. Importantly, during the final follow-up, both the numerical scores and the percentage of individuals displaying moderate to severe depression (15.5% vs. 9.4%, adjusted P<0.001) and anxiety (21.7% vs. 17.4%, adjusted P=0.025) were observably greater among HCWs compared to the general population (Figure 2).
Figure 2.Comparison of psychological consequences among the general population and HCWs during the first and second follow-up periods — Beijing Municipality, China, December 2022–April 2023.
Note: The scores for stress, depression, and anxiety from both groups were evaluated at the first and second follow-ups and are represented as points in the associated figure. Furthermore, the prevalence of moderate to severe stress, depression, and anxiety in the observed sample was computed and illustrated as bars in the same figure. The comparative analysis between the community and HCW cohorts was executed using log-binomial regression. Potential confounders, which include age, gender proportions, medical history, and vaccination status, were accounted for in the analysis. It should be noted that “1ST” and “2ND” refer to the initial and subsequent follow-ups, respectively.
Abbreviation: HCWs=healthcare workers; ad-P=adjusted-P.
HTML
Citation: |